AfterRaise/Companies/BrainChild Bio

BrainChild Bio

BrainChild Bio is a provider of CAR T cell therapies to treat tumors in the central nervous system. From its funding announcement.

$116M Series ARaised 46 days agoSeattle, USABiotech & PharmaUSA
Visit website →

In their own words

What BrainChild Bio says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "provider of CAR T cell therapies to treat tumors in the central nervous system". Source

Why now

Where BrainChild Bio is today

BrainChild Bio announced a Series A round of $116M on 8 September 2026, led by an undisclosed private family fund and foundation.

Latest round
Series A
Amount
$116M
Announced
8 September 2026
Headquarters
Seattle, USA
Sector
Biotech & Pharma
Investors
Also participating
Seattle Children's, WRF Capital
Relevant leadership
CEO Steven Brugger

Momentum AfterRaise intelligence

AfterRaise Score

71
Building momentum
1 funding signal in the last 90 days
Funding recency
34/40
announced within the last 60 days
Round scale
22/25
round size relative to the market
Funding stage
15/20
Series A
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 8 September 2026
    $116M Series A
    Led by an undisclosed private family fund and foundation.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Aggressive multi-front expansion
  • Senior executive hiring
  • Repeatable go-to-market build
  • First senior commercial hires

Opportunities this could create

  • Clinical operations
  • Regulatory affairs
  • CMC and manufacturing
  • Quality systems
  • Medical affairs

Based on the Biotech & Pharma sector and a Series A round. Not a statement of fact.

Early momentum1 connected signal
  • 8 September 2026$116M Series A announced

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What BrainChild Bio is open to

Not yet specified

BrainChild Bio has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with BrainChild Bio

All opportunities
OpportunityJOBPublic signal18 days ago
BrainChild Bio
Seattle, WA

Director, Program Lead

BrainChild Bio is hiring for this role on its own job board, after raising $116M.

Who they want
Approach preferences not yet specified
Apply on BrainChild Bio’s site →Company page
OpportunityJOBPublic signal58 days ago
BrainChild Bio
United States

Director, CMC Quality

BrainChild Bio is hiring for this role on its own job board, after raising $116M.

Who they want
Approach preferences not yet specified
Apply on BrainChild Bio’s site →Company page
OpportunityJOBPublic signal3 months ago
BrainChild Bio
United States

Director, Regulatory Affairs, CMC

BrainChild Bio is hiring for this role on its own job board, after raising $116M.

Who they want
Approach preferences not yet specified
Apply on BrainChild Bio’s site →Company page

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at BrainChild Bio?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: what the round is for, in your words. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector